JP4563447B2 - 不安、抑うつ及びてんかんの処置のためのｇａｂａレセプターリガンドとしての４−（スルファニル−ピリミジン−４−イルメチル）−モルホリン誘導体及び関連する化合物 - Google Patents
不安、抑うつ及びてんかんの処置のためのｇａｂａレセプターリガンドとしての４−（スルファニル−ピリミジン−４−イルメチル）−モルホリン誘導体及び関連する化合物 Download PDFInfo
- Publication number
- JP4563447B2 JP4563447B2 JP2007501167A JP2007501167A JP4563447B2 JP 4563447 B2 JP4563447 B2 JP 4563447B2 JP 2007501167 A JP2007501167 A JP 2007501167A JP 2007501167 A JP2007501167 A JP 2007501167A JP 4563447 B2 JP4563447 B2 JP 4563447B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- ylmethyl
- hexylsulfanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1nc(S)nc(CN(*)*)c1 Chemical compound *c1nc(S)nc(CN(*)*)c1 0.000 description 1
- YVHMREVZNIZPOW-UHFFFAOYSA-N CCCOC1(CCN(C)CC1)O Chemical compound CCCOC1(CCN(C)CC1)O YVHMREVZNIZPOW-UHFFFAOYSA-N 0.000 description 1
- AFXMWPJJZSIUHD-UHFFFAOYSA-N CN(CC1)CCC11OCCC1 Chemical compound CN(CC1)CCC11OCCC1 AFXMWPJJZSIUHD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100830 | 2004-03-02 | ||
| PCT/EP2005/001814 WO2005094828A1 (en) | 2004-03-02 | 2005-02-22 | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007526266A JP2007526266A (ja) | 2007-09-13 |
| JP2007526266A5 JP2007526266A5 (https=) | 2010-07-22 |
| JP4563447B2 true JP4563447B2 (ja) | 2010-10-13 |
Family
ID=34896109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501167A Expired - Fee Related JP4563447B2 (ja) | 2004-03-02 | 2005-02-22 | 不安、抑うつ及びてんかんの処置のためのｇａｂａレセプターリガンドとしての４−（スルファニル−ピリミジン−４−イルメチル）−モルホリン誘導体及び関連する化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7351700B2 (https=) |
| EP (1) | EP1725239B1 (https=) |
| JP (1) | JP4563447B2 (https=) |
| KR (1) | KR100802863B1 (https=) |
| CN (1) | CN1925859B (https=) |
| AT (1) | ATE367163T1 (https=) |
| AU (1) | AU2005229505B2 (https=) |
| BR (1) | BRPI0508310A (https=) |
| CA (1) | CA2557719A1 (https=) |
| DE (1) | DE602005001696T2 (https=) |
| ES (1) | ES2290885T3 (https=) |
| PL (1) | PL1725239T3 (https=) |
| RU (1) | RU2382033C2 (https=) |
| WO (1) | WO2005094828A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2353619C2 (ru) | 2007-06-28 | 2009-04-27 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции |
| RU2354647C2 (ru) * | 2007-06-28 | 2009-05-10 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе |
| CA2692945A1 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Compounds - 945 |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| KR102269132B1 (ko) | 2014-06-10 | 2021-06-25 | 삼성디스플레이 주식회사 | 반방향족성 화합물 및 이를 포함하는 유기 발광 소자 |
| US10084141B2 (en) | 2014-06-13 | 2018-09-25 | Samsung Display Co., Ltd. | Antiaromatic compound and organic light-emitting device including the same |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| TWI907472B (zh) | 2020-08-05 | 2025-12-11 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414199D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel Compounds |
| GB202414200D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414192D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| WO2001056990A2 (en) | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| CA2444148A1 (en) * | 2001-04-11 | 2002-10-24 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| GB0209481D0 (en) | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-22 KR KR1020067017683A patent/KR100802863B1/ko not_active Expired - Fee Related
- 2005-02-22 AT AT05707562T patent/ATE367163T1/de active
- 2005-02-22 AU AU2005229505A patent/AU2005229505B2/en not_active Ceased
- 2005-02-22 CN CN2005800066192A patent/CN1925859B/zh not_active Expired - Fee Related
- 2005-02-22 CA CA002557719A patent/CA2557719A1/en not_active Abandoned
- 2005-02-22 JP JP2007501167A patent/JP4563447B2/ja not_active Expired - Fee Related
- 2005-02-22 WO PCT/EP2005/001814 patent/WO2005094828A1/en not_active Ceased
- 2005-02-22 DE DE602005001696T patent/DE602005001696T2/de not_active Expired - Lifetime
- 2005-02-22 BR BRPI0508310-9A patent/BRPI0508310A/pt not_active IP Right Cessation
- 2005-02-22 PL PL05707562T patent/PL1725239T3/pl unknown
- 2005-02-22 EP EP05707562A patent/EP1725239B1/en not_active Expired - Lifetime
- 2005-02-22 ES ES05707562T patent/ES2290885T3/es not_active Expired - Lifetime
- 2005-02-22 RU RU2006134632/04A patent/RU2382033C2/ru not_active IP Right Cessation
- 2005-02-23 US US11/064,046 patent/US7351700B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100802863B1 (ko) | 2008-02-12 |
| WO2005094828A1 (en) | 2005-10-13 |
| KR20060116240A (ko) | 2006-11-14 |
| EP1725239B1 (en) | 2007-07-18 |
| RU2006134632A (ru) | 2008-04-10 |
| EP1725239A1 (en) | 2006-11-29 |
| DE602005001696D1 (de) | 2007-08-30 |
| US20050197337A1 (en) | 2005-09-08 |
| CN1925859B (zh) | 2010-11-24 |
| AU2005229505A1 (en) | 2005-10-13 |
| AU2005229505B2 (en) | 2010-07-15 |
| BRPI0508310A (pt) | 2007-07-24 |
| DE602005001696T2 (de) | 2008-04-10 |
| CA2557719A1 (en) | 2005-10-13 |
| PL1725239T3 (pl) | 2007-12-31 |
| ES2290885T3 (es) | 2008-02-16 |
| US7351700B2 (en) | 2008-04-01 |
| JP2007526266A (ja) | 2007-09-13 |
| CN1925859A (zh) | 2007-03-07 |
| RU2382033C2 (ru) | 2010-02-20 |
| ATE367163T1 (de) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101432112B1 (ko) | 도파민 ｄ3 수용체 리간드로서의 신규 카보닐화된 (아자)사이클로헥산 | |
| JP3940359B2 (ja) | 化合物 | |
| JP4563447B2 (ja) | 不安、抑うつ及びてんかんの処置のためのｇａｂａレセプターリガンドとしての４−（スルファニル−ピリミジン−４−イルメチル）−モルホリン誘導体及び関連する化合物 | |
| KR100912145B1 (ko) | Ｇａｂａ-ｂ 알로스테릭성 개선제로서 티에노-피리딘유도체 | |
| JPH10512598A (ja) | ノイロキニンレセプター拮抗薬としての５−アザビシクロ［３．１．０］ヘキシルアルキル−２−ピペリドンおよび−グルタルイミド | |
| JP2022081656A (ja) | モルヒナン誘導体 | |
| JP2002530377A (ja) | Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしてのキノリン−４−カルボキシアミド誘導体 | |
| JP2007527883A (ja) | インドール−１−イル酢酸誘導体 | |
| WO2010139717A1 (de) | Neue verbindungen | |
| JPH0568474B2 (https=) | ||
| JP5467044B2 (ja) | Ｔｓｈ受容体拮抗性のテトラヒドロキノリン化合物 | |
| WO2018052114A1 (ja) | モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用 | |
| TWI421079B (zh) | 二苯并〔ｂ，ｆ〕〔１，４〕氧氮呯化合物 | |
| JP2008517963A (ja) | Ｇａｂａ−ｂ受容体のアロステリックエンハンサーとしてのキノリン | |
| KR20010042904A (ko) | 광학 활성 테트라하이드로벤즈인돌 유도체 | |
| DE602005006018T2 (de) | Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden | |
| TW201930311A (zh) | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 | |
| WO2018066532A1 (ja) | モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用 | |
| KR20130069646A (ko) | 이미다조［１，２－ａ］피리딘 유도체 | |
| PT780388E (pt) | Ligandos de 5ht1dalfa e 5ht2 | |
| MXPA06009949A (es) | Derivados 4-(sulfanil-pirimidin-4-ilmetil)-morfolina y compuestos relacionados como ligandos del receptor gaba para el tratamiento contra ansiedad, depresion y epilepsia | |
| JPH0741481A (ja) | 両性型三環系化合物 | |
| JPH06247972A (ja) | ５−フェニル−ピロロ−１，４−ベンゾオキサジン−および−トリアジン−誘導体、その製造方法およびその製造のための中間体、およびそれを含有する抗アレルギー作用を有する医薬 | |
| DE60206253T2 (de) | Piperazinderivative als tachykinin antagonisten | |
| WO1994011363A1 (fr) | Derive de 2-alcoxy-5,6,7,8-tetrahydroquinoxaline, son procede de production, et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100604 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100604 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100706 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100728 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130806 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |